Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited has announced the cessation of Megan Clark as a director, effective October 28, 2025. This change in the board composition is accompanied by details of her interests in the company’s securities, which include 3,883 ordinary fully paid shares held directly and additional shares and rights held indirectly through Solium Nominees (Australia) Pty Ltd. This update is part of CSL’s compliance with regulatory requirements and may influence stakeholders’ perspectives on the company’s governance and strategic direction.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$275.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biopharmaceutical industry, focusing on the development and delivery of innovative medicines and vaccines. The company is known for its contributions to global health through its extensive range of products and services, catering to various healthcare needs worldwide.
Average Trading Volume: 1,206,320
Technical Sentiment Signal: Sell
Current Market Cap: A$103.1B
Learn more about CSL stock on TipRanks’ Stock Analysis page.